As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Recently, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science and South China Center for Innovative Pharmaceuticals’ “Class 1.1 piperazine da ketone chemical drugs” (AD16) was officially accepted by CFDA for clinical trial.
Medicilon was responsible for the pharmacokinetic and safety evaluation of AD16. The result of preclinical evaluation showed that AD16 is safe and its metabolites are simple. AD16 has high druggability and development prospects.
AD16 mainly focuses on Alzheimer’s disease. According to the China Association of Alzheimer’s in 2013, there were about 6 million patients who suffered Alzheimer’s disease in China. If AD16 were successfully developed, there would be a new treatment for Alzheimer’s disease.
Share：
Relevant
news
marketing@medicilon.com
ABOUT
